Current clinical development of PI3K pathway inhibitors in glioblastoma

Challenges in the clinical development of PI3K inhibitors

The PI3K/Akt/mTOR pathway is one of the most frequently dysregulated signaling pathways in cancer and an important target for drug development. PI3K signaling plays a fundamental role in tumorigenesis, governing cell proliferation, survival, motility, and angiogenesis. Activation of the pathway is frequently observed in a variety of tumor types and can occur through several mechanisms. These me...

development of feminist poetics in adrienne rich

اشعار ریچ، به عنوان اشعاری که همیشه در حال تغییر و دگرگونی هستند، تجسمی از رشد و دگرگونیِ انسان هستد. پایان نامه ی حاضر، با تمرکز بر روی مراحل سیر شعری ریچ از تغییری در دنیا به عکس هایی فوری از یک عروس، سپس به شیرجه به درون کشتی شکسته و در نهایت به صبری عجیب مرا تا اینجا آورده، به بررسی این مراحل در قالب نظر شوالتر در رابطه با سه مرحله ی پیشرفت ادبی زنان یعنی مرحله ی زنانه، زن گرا و زن محور می پ...

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

Glioblastoma multiform (GBM) is the most common malignant glioma of all the brain tumors and currently effective treatment options are still lacking. GBM is frequently accompanied with overexpression and/or mutation of epidermal growth factor receptor (EGFR), which subsequently leads to activation of many downstream signal pathways such as phosphatidylinositol 3-kinase (PI3K)/Akt/rapamycin-sens...

Erlotinib in Glioblastoma – A Current Clinical Perspective

Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics.

The phosphatidylinositol 3-kinase (PI3K) signaling pathway is integral to many essential cell processes, including cell growth, differentiation, proliferation, motility, and metabolism. Somatic mutations and genetic amplifications that result in activation of the pathway are frequently detected in cancer. This has led to the development of rationally designed therapeutics targeting key members ...